undamentalytics Newsletter
Sign in

4d Molecular Therapeutics, Inc. revenue

4d Molecular Therapeutics, Inc.'s revenue was $85.2m in fiscal 2025, up 230194.6% on the year before. Since fiscal 2019 ($7.0m) it has grown at a compound 51.7% a year. Over the last twelve months it was $92.0m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue7141832108592
Growth on the year before—+94.8%+32.5%−82.7%+562.3%−99.8%+>999%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
Japan $85M 99.8% —
United States $209,000 0.2% ▲ 464.9%

From 4d Molecular Therapeutics, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
4d Molecular Therapeutics, Inc. $92.0m 278712.1% 242.8%
Verastem, Inc. $87.5m 26.4% 58.4%
Agios Pharmaceuticals, Inc. $98.3m 140.6% 69.6%
Septerna, Inc. $98.9m 13520.1% —
Bicycle Therapeutics PLC $83.5m 194.7% 49.8%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%

Compare with peers

Head to head: FDMT vs VSTMAGIO vs FDMTFDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from 4d Molecular Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 4d Molecular Therapeutics, Inc.